nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
Company profile
Ticker
NNVC
Exchange
Website
CEO
Anil R. Diwan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
760674577
NNVC stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
5 Apr 24
424B5
Prospectus supplement for primary offering
5 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
DEF 14A
Definitive proxy
4 Dec 23
10-Q
2024 Q1
Quarterly report
14 Nov 23
8-K
Other Events
6 Nov 23
10-K
2023 FY
Annual report
13 Oct 23
NT 10-K
Notice of late annual filing
28 Sep 23
Latest ownership filings
4
Anil Diwan
10 Aug 22
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
Altium Capital Management LP
12 Feb 21
SC 13G/A
Empery Asset Management, LP
26 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
4 Jan 21
SC 13G
Altium Capital Management LP
20 Jul 20
SC 13G
CVI Investments, Inc.
29 May 20
3
Makarand Jawadakar
1 May 20
SC 13G
Nanoviricides, Inc.
27 Jan 20
SC 13G/A
Nanoviricides, Inc.
24 Jan 20
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.97 mm | 6.97 mm | 6.97 mm | 6.97 mm | 6.97 mm | 6.97 mm |
Cash burn (monthly) | 393.33 k | 495.69 k | 677.20 k | 779.39 k | 390.56 k | 484.07 k |
Cash used (since last report) | 2.71 mm | 3.41 mm | 4.66 mm | 5.36 mm | 2.69 mm | 3.33 mm |
Cash remaining | 4.26 mm | 3.56 mm | 2.31 mm | 1.61 mm | 4.28 mm | 3.64 mm |
Runway (months of cash) | 10.8 | 7.2 | 3.4 | 2.1 | 11.0 | 7.5 |
Institutional ownership, Q3 2023
10.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 8 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.48 bn |
Total shares | 1.20 mm |
Total puts | 500.00 |
Total calls | 27.00 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 458.42 k | $614.28 mm |
BLK Blackrock | 160.95 k | $215.67 mm |
Compagnie Lombard Odier SCmA | 150.00 k | $201.00 mm |
Geode Capital Management | 109.49 k | $146.77 mm |
Renaissance Technologies | 76.10 k | $102.00 k |
Bridgeway Capital Management | 59.04 k | $79.11 mm |
STT State Street | 41.91 k | $56.15 mm |
RY Royal Bank Of Canada | 30.54 k | $41.00 mm |
Susquehanna International | 29.41 k | $39.41 mm |
SF Stifel Financial | 21.20 k | $28.41 mm |
News
EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
16 Feb 24
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
15 Feb 24
Press releases
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
15 Feb 24
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
1 Feb 24
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
29 Jan 24